Amy E. McKee

3.9k total citations
37 papers, 2.3k citations indexed

About

Amy E. McKee is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Amy E. McKee has authored 37 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Amy E. McKee's work include Lung Cancer Treatments and Mutations (8 papers), Cancer Genomics and Diagnostics (7 papers) and Statistical Methods in Clinical Trials (5 papers). Amy E. McKee is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Cancer Genomics and Diagnostics (7 papers) and Statistical Methods in Clinical Trials (5 papers). Amy E. McKee collaborates with scholars based in United States, France and Canada. Amy E. McKee's co-authors include Richard Pazdur, Kirsten B. Goldberg, Gideon M. Blumenthal, Carol J. Thiele, Patricia Keegan, Zhijie Li, Kun He, Sriram Subramaniam, Rajeshwari Sridhara and Ann T. Farrell and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Amy E. McKee

37 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy E. McKee United States 24 1.3k 686 605 370 339 37 2.3k
Morten Mau‐Sørensen Denmark 28 1.2k 0.9× 1.1k 1.6× 527 0.9× 276 0.7× 541 1.6× 130 2.7k
Yoichi Naito Japan 27 1.7k 1.3× 623 0.9× 1.1k 1.8× 355 1.0× 428 1.3× 150 2.7k
Scott Cruickshank United States 21 1.2k 0.9× 741 1.1× 1.0k 1.7× 349 0.9× 368 1.1× 56 2.6k
Benoît Lhermitte France 18 710 0.5× 821 1.2× 702 1.2× 160 0.4× 647 1.9× 77 2.5k
Ben Markman Australia 24 1.2k 0.9× 1.3k 1.9× 489 0.8× 219 0.6× 329 1.0× 75 2.5k
Jennifer R. Diamond United States 26 2.0k 1.5× 998 1.5× 756 1.2× 466 1.3× 469 1.4× 136 3.0k
Stephen Leong United States 23 1.1k 0.9× 842 1.2× 471 0.8× 178 0.5× 606 1.8× 73 2.3k
In Ah Kim South Korea 29 987 0.7× 1.1k 1.5× 757 1.3× 189 0.5× 874 2.6× 162 3.0k
Jean‐Sébastien Frenel France 26 1.4k 1.0× 801 1.2× 809 1.3× 350 0.9× 708 2.1× 188 2.7k
Laura Boldrini Italy 27 916 0.7× 1.2k 1.7× 733 1.2× 167 0.5× 652 1.9× 98 2.5k

Countries citing papers authored by Amy E. McKee

Since Specialization
Citations

This map shows the geographic impact of Amy E. McKee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy E. McKee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy E. McKee more than expected).

Fields of papers citing papers by Amy E. McKee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy E. McKee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy E. McKee. The network helps show where Amy E. McKee may publish in the future.

Co-authorship network of co-authors of Amy E. McKee

This figure shows the co-authorship network connecting the top 25 collaborators of Amy E. McKee. A scholar is included among the top collaborators of Amy E. McKee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy E. McKee. Amy E. McKee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bruno, René, Jin Y. Jin, Kimberly Maxfield, et al.. (2019). Proceedings of a Workshop: US Food and Drug Administration‐International Society of Pharmacometrics Model‐Informed Drug Development in Oncology. Clinical Pharmacology & Therapeutics. 106(1). 81–83. 1 indexed citations
2.
Suzman, Daniel L., Sundeep Agrawal, V. Ellen Maher, et al.. (2018). FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. The Oncologist. 24(4). 563–569. 138 indexed citations
3.
Odogwu, Lauretta, Luckson Mathieu, Gideon M. Blumenthal, et al.. (2018). FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations. The Oncologist. 23(6). 740–745. 166 indexed citations
4.
Pelosof, Lorraine, Steven J. Lemery, Sandra J. Casak, et al.. (2018). Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib. The Oncologist. 23(4). 496–500. 15 indexed citations
5.
Pulte, Dianne, Jonathon Vallejo, Donna Przepiorka, et al.. (2018). FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia. The Oncologist. 23(11). 1366–1371. 44 indexed citations
6.
O’Neal, Patricia, Virginia E. Kwitkowski, Lola Luo, et al.. (2018). FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation. The Oncologist. 23(12). 1520–1524. 53 indexed citations
7.
Fashoyin‐Aje, Lola A., Martha Donoghue, Huanyu Chen, et al.. (2018). FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1. The Oncologist. 24(1). 103–109. 171 indexed citations
8.
9.
Pai-Scherf, Lee H., Gideon M. Blumenthal, Hongshan Li, et al.. (2017). FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. The Oncologist. 22(11). 1392–1399. 228 indexed citations
10.
11.
Goldberg, Kirsten B., Gideon M. Blumenthal, Amy E. McKee, & Richard Pazdur. (2017). The FDA Oncology Center of Excellence and precision medicine. Experimental Biology and Medicine. 243(3). 308–312. 28 indexed citations
12.
McKee, Amy E., et al.. (2017). How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?. The Journal of Clinical Pharmacology. 57(S10). S136–S142. 26 indexed citations
13.
Blumenthal, Gideon M., Paul G. Kluetz, Julie A. Schneider, et al.. (2017). Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies. The Oncologist. 22(7). 762–767. 48 indexed citations
14.
Beaver, Julia A., Abraham Tzou, Gideon M. Blumenthal, et al.. (2016). An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies. Clinical Cancer Research. 23(6). 1368–1372. 26 indexed citations
15.
Lemery, Steven J., M. Ricci, Patricia Keegan, Amy E. McKee, & Richard Pazdur. (2016). FDA's Approach to Regulating Biosimilars. Clinical Cancer Research. 23(8). 1882–1885. 23 indexed citations
16.
Ricks, Tiffany K., Haw-Jyh Chiu, Gwynn Ison, et al.. (2015). Successes and Challenges of PARP Inhibitors in Cancer Therapy. Frontiers in Oncology. 5. 222–222. 57 indexed citations
17.
McKee, Amy E., Ann T. Farrell, Richard Pazdur, & Janet Woodcock. (2010). The Role of the U.S. Food and Drug Administration Review Process: Clinical Trial Endpoints in Oncology. The Oncologist. 15(S1). 13–18. 61 indexed citations
18.
Hansford, Loen M., Amy E. McKee, Libo Zhang, et al.. (2007). Neuroblastoma Cells Isolated from Bone Marrow Metastases Contain a Naturally Enriched Tumor-Initiating Cell. Cancer Research. 67(23). 11234–11243. 132 indexed citations
19.
McKee, Amy E. & Carol J. Thiele. (2006). Targeting caspase 8 to reduce the formation of metastases in neuroblastoma. Expert Opinion on Therapeutic Targets. 10(5). 703–708. 14 indexed citations
20.
McKee, Amy E., K. Martin, Ana Marković, et al.. (2006). BDNF/TrkB pathway upregulates PTHrP in neuroblastoma. 66. 936–936. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Morten Mau‐Sørensen Breakdown of academic impact, for papers by Yoichi Naito Breakdown of academic impact, for papers by Scott Cruickshank Breakdown of academic impact, for papers by Benoît Lhermitte Breakdown of academic impact, for papers by Ben Markman Breakdown of academic impact, for papers by Jennifer R. Diamond Breakdown of academic impact, for papers by Stephen Leong Breakdown of academic impact, for papers by In Ah Kim Breakdown of academic impact, for papers by Jean‐Sébastien Frenel Breakdown of academic impact, for papers by Laura Boldrini
Rankless by CCL
2026